In this episode of Meeting Mic, we bring you pearls and perspectives in metastatic breast cancer from the American Society of Clinical Oncology 2026. In an interview, Shimoli Barot, MD, discusses a genomic test which could be used to identify patients with ER-positive, HER2-negative breast cancer who may be able to avoid chemotherapy. Next, Erika P. Hamilton, MD, discusses the HER2-CLIMB05 trial for patients with HER2-positive metastatic breast cancer. And, Sherry Shen, MD, discusses lifestyle and survivorship for patients with breast cancer, specifically with GLP-1 use. Read the full coverage here: VIDEO: Genetic test helps identify patients with breast cancer who may avoid chemotherapy Source: Healio Interviews VIDEO: Tucatinib plus trastuzumab, pertuzumab safe for HER2-positive breast cancer Source: Hamilton EP. Abstract 1005. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago. VIDEO: Less weight loss, improved survival for GLP-1 use in women with breast cancer Source: Shen S. Optimizing breast cancer survivorship: Addressing lifestyle, weight management, and psychological health. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago. 'Critically important': Upfront sacituzumab govitecan combo benefits breast cancer subset Source: Kalinsky K, et al. Abstract LBA1000. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago. 'Real value': Remote program significantly improves physical function in breast cancer Source: Ligibel JA, et al. Abstract 12010. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago. Barot and Shen report no relevant financial disclosures. Hamilton reports receiving research funding from Abbvie, Accutar Biotechnology, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, BeOne Medicines, Bicycle Therapeutics, Biohaven Pharmaceuticals, BioNTech, Compugen, Cullinan, Daiichi Sankyo, Dantari, Day One Biopharmaceuticals, Duality Biologics, Ellipses Pharma, Elucida Oncology, Exelixis, FujiFilm, Genmab, Gilead Sciences, H3 Biomedicine, Iambic Therapeutics, Immunogen, Inspirna, InventisBio, Jacobio, Jazz Pharmaceuticals, K-Group Beta, Kind Pharmaceuticals, Lilly, Loxo Oncology, Mabspace Biosciences, Mabwell Bioscience, Marengo Therapeutics, MediLink Therapeutics, Merck, Mersana, Novartis, Olema, Orinove, Orum Therapeutics, Pfizer, Pionyr Immunotherapeutics, Prelude Therapeutics, Profound Bio, Regeneron, Relay Therapeutics, Rgenix, Roche/Genentech, SeaGen, Shattuck Labs, Simcha Therapeutics, Stemline Therapeutics, Sutro, Systimmune, Taiho, Tesaro, TheRas, Treadwell Therapeutics, Verastem, Xadcera Biopharmaceutical and Zymeworks; and consulted or advised for ADC Therapeutics, Arvinas, AstraZeneca, BeOne Medicines, BicycleTx, BioNTech, Boehringer Ingelheim, Boundless Bio, Bristol-Myers Squibb, Daiichi Sankyo, Gilead Sciences, Halda Therapeutics, Hexagon Bio, Immunome, Incyclix Bio, Janssen, Jazz Pharmaceuticals, Lilly, Merck, Mersana Therapeutics, Novartis, Pfizer, Precede Biosciences, Pyxis Oncology, Rigel Pharmaceuticals, Roche/Genentech, Samsung Bioepis, Shorla Pharma and Stemline Therapeutics.